Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06561256
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-08-15
Brief Title:
JAK Inhibitors Efficacy in Bullous Pemphigoid
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Effectiveness and Safety of Combination Therapy With Corticosteroids and JAK Inhibitors in Bullous Pemphigoid
Status:
COMPLETED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Bullous pemphigoid BP is an autoimmune subepidermal blistering skin disease that predominantly affects the elderly population with rare cases reported in children and adolescents BP is characterized by circulating antibodies that target the hemidesmosomal proteins bullous pemphigoid Antigen 1 BPAg1 or BP230 and bullous pemphigoid Antigen 2 BPAg2 or BP180collagen XVII located at the dermal-epidermal junction The first-line treatment of BP includes topical or systemic use of corticosteroids For refractory cases or when corticosteroids are contraindicated or to minimize adverse effects adjunct therapies such as immunosuppressants eg azathioprine cyclosporine dapsone tetracycline antibiotics combined with niacinamide intravenous immunoglobulins IVIG and plasma exchange are employed Recent research has explored the use of biologic agents to treat refractory BP including anti-CD20 monoclonal antibodies anti-IgE monoclonal antibodies and anti-interleukin monoclonal antibodies showing promising outcomes Nevertheless effectively managing BP remains a challenge
The Janus kinase JAK-signal transducer and activator of transcription STAT pathway has been implicated as a key driver in many inflammatory diseases Recently a class of drugs targeting this pathway known as JAK inhibitors has been developed Some studies have investigated the efficacy and safety of JAK inhibitors combination with corticosteroids in BP treatment In this retrospective study the investigators conducted a comparative analysis to evaluate the efficacy and safety of JAK inhibitors combination With corticosteroids for patients diagnosed with moderate-to-severe bullous pemphigoid
The Janus kinase JAK-signal transducer and activator of transcription STAT pathway has been implicated as a key driver in many inflammatory diseases Recently a class of drugs targeting this pathway known as JAK inhibitors has been developed Some studies have investigated the efficacy and safety of JAK inhibitors combination with corticosteroids in BP treatment In this retrospective study the investigators conducted a comparative analysis to evaluate the efficacy and safety of JAK inhibitors combination With corticosteroids for patients diagnosed with moderate-to-severe bullous pemphigoid
Detailed Description:
This study will conduct a retrospective review of patients with Bullous pemphigoid in the Department of Dermatology of the First Affiliated Hospital of Fujian Medical University Researchers will initially screen patients based on the inclusion and exclusion criteria through their respective hospitals medical record systems at the beginning of the study All enrolled patients will be followed for a duration of 48 weeks This study will include approximately 300 patients with moderate to severe BP
The Primary outcomes were the time to cease of new lesions time to achieve minimal therapy the cumulative amount of corticosteroids at the time of achieving minimal therapy The Secondary outcomes were the scores of BPDAI week 0 week 2 and week 4 the scores of itching Numeric Rating Scale NRS week 0 week 2 and week 4 the level of IgE week 0 week 2 and eosinophil percentage Eos week 0 week 2 the clinical remissions at week 24 and week 48 Adverse events all treatment-related adverse events AEs were assessed
The statistical analysis was performed using GraphPad Prism software 100 and SPSS 290 Categorical variables were presented as frequencies and percentages Continuous variables were represented as means and standard deviations SD or as medians and interquartile ranges IQR Absolute and relative frequencies were used to describe qualitative variables Groups were compared using chi-square test for qualitative variables and independent sample t-test or analysis of variance ANOVA for quantitative variables with symmetric distribution The Mann-Whitney U test or Kruskal-Wallis test were used for quantitative variables with skewed distributions P 005 was considered statistically significant
Upon completion the study will analyze the collected data and to assess the efficacy and safety of the combination of Janus kinase inhibitors and corticosteroids in treatment of BP
The Primary outcomes were the time to cease of new lesions time to achieve minimal therapy the cumulative amount of corticosteroids at the time of achieving minimal therapy The Secondary outcomes were the scores of BPDAI week 0 week 2 and week 4 the scores of itching Numeric Rating Scale NRS week 0 week 2 and week 4 the level of IgE week 0 week 2 and eosinophil percentage Eos week 0 week 2 the clinical remissions at week 24 and week 48 Adverse events all treatment-related adverse events AEs were assessed
The statistical analysis was performed using GraphPad Prism software 100 and SPSS 290 Categorical variables were presented as frequencies and percentages Continuous variables were represented as means and standard deviations SD or as medians and interquartile ranges IQR Absolute and relative frequencies were used to describe qualitative variables Groups were compared using chi-square test for qualitative variables and independent sample t-test or analysis of variance ANOVA for quantitative variables with symmetric distribution The Mann-Whitney U test or Kruskal-Wallis test were used for quantitative variables with skewed distributions P 005 was considered statistically significant
Upon completion the study will analyze the collected data and to assess the efficacy and safety of the combination of Janus kinase inhibitors and corticosteroids in treatment of BP
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None